Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”

Published:2023-07 Issue:7 Volume:34 Page:
ISSN:0905-6157
Container-title:Pediatric Allergy and Immunology
language:en
Short-container-title:Pediatric Allergy Immunology

Author:

Akenroye Ayobami¹²^ORCID,Phipatanakul Wanda³

Affiliation:

1. Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine Harvard Medical School Boston Massachusetts USA

2. Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine Harvard Medical School Boston Massachusetts USA

3. Division of Immunology, Department of Pediatrics, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pai.13980

Reference12 articles.

1. World Health Organization [WHO].Asthma fact sheet. Accessed August 12 2019.https://www.who.int/news‐room/fact‐sheets/detail/asthma

2. Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019

3. Severe asthma: Epidemiology, burden of illness, and heterogeneity

4. Biologic Therapies for Severe Asthma

5. Preface

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP